MESO Q3 2018 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$991,000+10.0% YoY

Gross Profit

-$718,000-72.5% margin

Operating Income

-$24M-2382.1% margin

Net Income

-$21M-2132.9% margin

EPS (Diluted)

$-0.45

QoQ Revenue Growth

-92.5%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$678M

Total Liabilities

$122M

Stockholders' Equity

$556M

Cash & Equivalents

$59M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$991,000	$901,000	+10.0%
Gross Profit	-$718,000	-$3M	+75.5%
Operating Income	-$24M	-$22M	-7.3%
Net Income	-$21M	-$10M	-116.0%